MAPT and Alzheimer disease: By using KCa3.1 knockout mice, memory deficits, neuronal loss, glial activation, tau phosphorylation, and insulin signaling deficits were ameliorated compared with control animals, making this channel an interesting pharmacological target in AD [215].